Daily Papers

Deep learning-based image signal processor (ISP) models for mobile cameras can generate high-quality images that rival those of professional DSLR cameras. However, their computational demands often make them unsuitable for mobile settings. Additionally, modern mobile cameras employ non-Bayer color filter arrays (CFA) such as Quad Bayer, Nona Bayer, and QxQ Bayer to enhance image quality, yet most existing deep learning-based ISP (or demosaicing) models focus primarily on standard Bayer CFAs. In this study, we present PyNET-QxQ, a lightweight demosaicing model specifically designed for QxQ Bayer CFA patterns, which is derived from the original PyNET. We also propose a knowledge distillation method called progressive distillation to train the reduced network more effectively. Consequently, PyNET-QxQ contains less than 2.5% of the parameters of the original PyNET while preserving its performance. Experiments using QxQ images captured by a proto type QxQ camera sensor show that PyNET-QxQ outperforms existing conventional algorithms in terms of texture and edge reconstruction, despite its significantly reduced parameter count.

As the physical size of recent CMOS image sensors (CIS) gets smaller, the latest mobile cameras are adopting unique non-Bayer color filter array (CFA) patterns (e.g., Quad, Nona, QxQ), which consist of homogeneous color units with adjacent pixels. These non-Bayer sensors are superior to conventional Bayer CFA thanks to their changeable pixel-bin sizes for different light conditions but may introduce visual artifacts during demosaicing due to their inherent pixel pattern structures and sensor hardware characteristics. Previous demosaicing methods have primarily focused on Bayer CFA, necessitating distinct reconstruction methods for non-Bayer patterned CIS with various CFA modes under different lighting conditions. In this work, we propose an efficient unified demosaicing method that can be applied to both conventional Bayer RAW and various non-Bayer CFAs' RAW data in different operation modes. Our Knowledge Learning-based demosaicing model for Adaptive Patterns, namely KLAP, utilizes CFA-adaptive filters for only 1% key filters in the network for each CFA, but still manages to effectively demosaic all the CFAs, yielding comparable performance to the large-scale models. Furthermore, by employing meta-learning during inference (KLAP-M), our model is able to eliminate unknown sensor-generic artifacts in real RAW data, effectively bridging the gap between synthetic images and real sensor RAW. Our KLAP and KLAP-M methods achieved state-of-the-art demosaicing performance in both synthetic and real RAW data of Bayer and non-Bayer CFAs.

While large language models (LLMs) have shown promise in diagnostic dialogue, their capabilities for effective management reasoning - including disease progression, therapeutic response, and safe medication prescription - remain under-explored. We advance the previously demonstrated diagnostic capabilities of the Articulate Medical Intelligence Explorer (AMIE) through a new LLM-based agentic system optimised for clinical management and dialogue, incorporating reasoning over the evolution of disease and multiple patient visit encounters, response to therapy, and professional competence in medication prescription. To ground its reasoning in authoritative clinical knowledge, AMIE leverages Gemini's long-context capabilities, combining in-context retrieval with structured reasoning to align its output with relevant and up-to-date clinical practice guidelines and drug formularies. In a randomized, blinded virtual Objective Structured Clinical Examination (OSCE) study, AMIE was compared to 21 primary care physicians (PCPs) across 100 multi-visit case scenarios designed to reflect UK NICE Guidance and BMJ Best Practice guidelines. AMIE was non-inferior to PCPs in management reasoning as assessed by specialist physicians and scored better in both preciseness of treatments and investigations, and in its alignment with and grounding of management plans in clinical guidelines. To benchmark medication reasoning, we developed RxQA, a multiple-choice question benchmark derived from two national drug formularies (US, UK) and validated by board-certified pharmacists. While AMIE and PCPs both benefited from the ability to access external drug information, AMIE outperformed PCPs on higher difficulty questions. While further research would be needed before real-world translation, AMIE's strong performance across evaluations marks a significant step towards conversational AI as a tool in disease management.